January 27, 2026 — Innovasyn announced today that its ingredient NMN (β-Nicotinamide Mononucleotide) has been officially approved and filed as a new cosmetic ingredient by the National Medical Products Administration (NMPA) of China.
According to the public filing information released by the NMPA, Innovasyn’s NMN successfully completed the national new cosmetic ingredient filing process on January 27, 2026, under Filing No.: GZYBZ 20260018. This approval confirms that Innovasyn NMN meets China’s regulatory requirements for safety, quality, and compliance, allowing its compliant use in cosmetic formulations within the Chinese market.
The NMPA, as China’s national regulatory authority for pharmaceuticals, medical devices, and cosmetics, applies stringent oversight standards throughout the approval process. The successful filing signifies official national recognition of Innovasyn NMN as a compliant cosmetic raw material.
This milestone represents a significant step forward for Innovasyn in China’s rapidly growing anti-aging and functional skincare market. With this approval, NMN is now positioned for broader application in cosmetic products focused on skin vitality, aging care, and advanced skincare innovation.
Innovasyn stated that the approval underscores its continued commitment to regulatory compliance, product safety, and long-term investment in scientifically validated ingredients. The company will continue to support global partners with compliant NMN solutions tailored for the Chinese cosmetic market.
